Midazolam - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (19)Enzymes (7)Transporters (2)

Targets (19)Enzymes (7)Transporters (2)Biointeractions (32)

Identification

Name

Midazolam

Accession Number

DB00683 (APRD00680)

Type

Small Molecule

Groups

Approved, Illicit

Description

A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Buccolam

Dormicum

Midazolam

Midazolamum

External IDs

Dea No. 2884 / Ro 21-3981/001 / Ro 21-3981/003

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Midazolam Hydrochloride	W7TTW573JJ	59467-96-8	PLYSCVSCYOQVRP-UHFFFAOYSA-N	Details
Midazolam maleate	77520S18SE	59467-94-6	XYGVIBXOJOOCFR-BTJKTKAUSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Buccolam	Solution	2.5 mg	Buccal	Shire Services Bvba	2011-09-05	Not applicable	EU
Buccolam	Solution	10 mg	Buccal	Shire Services Bvba	2011-09-05	Not applicable	EU
Buccolam	Solution	5 mg	Buccal	Shire Services Bvba	2011-09-05	Not applicable	EU
Buccolam	Solution	7.5 mg	Buccal	Shire Services Bvba	2011-09-05	Not applicable	EU
Midazolam Injection	Solution	1 mg	Intramuscular; Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable	Canada
Midazolam Injection	Solution	5 mg	Intramuscular; Intravenous	Pfizer	2015-03-31	Not applicable	Canada
Midazolam Injection	Solution	1 mg	Intramuscular; Intravenous	Sandoz Canada Incorporated	1999-07-21	Not applicable	Canada
Midazolam Injection	Solution	5 mg	Intramuscular; Intravenous	Novopharm Limited	2001-12-17	Not applicable	Canada
Midazolam Injection	Liquid	5 mg	Intramuscular; Intravenous	Fresenius Kabi	2001-03-26	Not applicable	Canada
Midazolam Injection	Solution	5 mg	Intramuscular; Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable	Canada
Midazolam Injection	Solution	5 mg	Intramuscular; Intravenous	Sandoz Canada Incorporated	1999-07-21	Not applicable	Canada
Midazolam Injection	Solution	1 mg	Intramuscular; Intravenous	Fresenius Kabi	2001-03-26	Not applicable	Canada
Midazolam Injection	Solution	1 mg	Intramuscular; Intravenous	Pfizer	2015-03-31	Not applicable	Canada
Midazolam Injection	Solution	1 mg	Intramuscular; Intravenous	Novopharm Limited	2001-12-17	Not applicable	Canada
Midazolam Injection BP	Solution	5 mg	Intramuscular; Intravenous	Hospira, Inc.	Not applicable	Not applicable	Canada
Midazolam Injection BP	Solution	1 mg	Intramuscular; Intravenous	Hospira, Inc.	Not applicable	Not applicable	Canada
Midazolam Injection Sdz	Solution	5 mg	Intramuscular; Intravenous	Sandoz Canada Incorporated	2012-07-26	Not applicable	Canada
Midazolam Injection Sdz	Solution	1 mg	Intramuscular; Intravenous	Sandoz Canada Incorporated	2012-07-26	Not applicable	Canada
Midazolam Injection USP	Solution	5 mg	Intramuscular; Intravenous	Hospira, Inc.	2016-02-16	Not applicable	Canada
Midazolam Injection USP	Solution	1 mg	Intramuscular; Intravenous	Hospira, Inc.	2015-03-30	Not applicable	Canada
Midazolam Injection USP	Solution	1 mg	Intramuscular; Intravenous	Hospira, Inc.	2016-06-15	Not applicable	Canada
Midazolam Injection USP	Solution	5 mg	Intramuscular; Intravenous	Hospira, Inc.	2016-02-09	Not applicable	Canada
PMS-midazolam	Liquid	1 mg	Intramuscular; Intravenous	Pharmascience Inc	Not applicable	Not applicable	Canada
PMS-midazolam	Liquid	5 mg	Intramuscular; Intravenous	Pharmascience Inc	Not applicable	Not applicable	Canada
Versed Inj 1mg/ml	Liquid	1 mg	Intramuscular; Intravenous	Hoffmann La Roche	1989-12-31	2004-07-07	Canada
Versed Inj 5mg/ml	Liquid	5 mg	Intramuscular; Intravenous	Hoffmann La Roche	1988-12-31	2004-06-28	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-midazolam Injectable 1 mg/ml	Liquid	1 mg	Intramuscular; Intravenous	Apotex Corporation	2001-04-10	2013-08-02	Canada
Apo-midazolam Injectable 5 mg/ml	Liquid	5 mg	Intramuscular; Intravenous	Apotex Corporation	2001-04-10	2013-08-02	Canada
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-20	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-10	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Sagent Pharmaceuticals	2012-03-19	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Fresenius Kabi	2014-10-03	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	Caraco Pharmaceutical Laboratories, Ltd.	2012-08-08	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	Akorn	2005-05-06	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	Caraco Pharmaceutical Laboratories, Ltd.	2012-08-08	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Athenex Pharmaceutical Division, Llc.	2016-12-14	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Sagent Pharmaceuticals	2012-03-19	Not applicable	US
Midazolam	Injection, solution	2 mg/2mL	Intramuscular; Intravenous	Fresenius Kabi	2014-10-03	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-20	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-07-14	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	A S Medication Solutions	2000-06-20	2017-06-20	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-20	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection, solution	10 mg/2mL	Intramuscular; Intravenous	Fresenius Kabi	2014-10-03	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Sagent Pharmaceuticals	2012-03-19	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	APP Pharmaceuticals, Inc.	2000-07-14	Not applicable	US
Midazolam	Injection, solution	2 mg/2mL	Intramuscular; Intravenous	Athenex Pharmaceutical Division, Llc.	2016-12-14	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	Akorn	2005-05-06	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Sagent Pharmaceuticals	2012-03-19	Not applicable	US
Midazolam	Injection, solution	1 mg/mL	Intramuscular; Intravenous	APP Pharmaceuticals, Inc.	2000-07-10	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	The Medicines Company	2000-07-14	Not applicable	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-20	Not applicable	US
Midazolam	Injection	5 mg/mL	Intramuscular; Intravenous	A S Medication Solutions	2000-06-20	2017-06-20	US
Midazolam	Injection	1 mg/mL	Intramuscular; Intravenous	West Ward Pharmaceutical	2000-06-20	Not applicable	US
Midazolam	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-07-14	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Atlantic Biologicals Corps.	2002-07-05	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2010-03-04	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-05-30	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Baxter Laboratories	2010-03-04	2015-12-29	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Gland Pharma Limited	2012-06-01	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Ranbaxy Inc.	2002-07-05	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Paddock Laboratories, Inc.	2005-05-02	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-05-30	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Physicians Total Care, Inc.	2006-12-12	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2002-07-22	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Precision Dose, Inc.	2015-05-26	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2002-06-13	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-21	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Dispensing Solutions, Inc.	2011-05-03	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2000-06-20	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-11-10	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2002-07-22	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	A S Medication Solutions	2000-06-20	2017-06-20	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2010-03-04	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Atlantic Biologicals Corps.	2002-04-30	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-11-10	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Heritage	2016-11-07	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	Precision Dose, Inc.	2015-05-26	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2002-06-13	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-05-30	Not applicable	US
Midazolam Hydrochloride	Injection	2 mg/2mL	Intramuscular; Intravenous	Cardinal Health	2000-06-21	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2002-06-13	Not applicable	US
Midazolam Hydrochloride	Injection	10 mg/2mL	Intramuscular; Intravenous	Cardinal Health	2000-06-21	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-05-30	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Baxter Laboratories	2010-03-04	2015-12-29	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Gland Pharma Limited	2012-06-01	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	General Injectables & Vaccines	2010-08-01	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2002-07-22	Not applicable	US
Midazolam Hydrochloride	Syrup	2 mg/mL	Oral	West Ward Pharmaceutical	2002-04-30	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	A S Medication Solutions	2000-06-20	2017-06-20	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2002-07-22	Not applicable	US
Midazolam Hydrochloride	Syrup	10 mg/5mL	Oral	Precision Dose, Inc.	2010-10-11	2016-08-31	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Cardinal Health	2005-08-03	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-11-10	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Heritage	2016-11-08	Not applicable	US
Midazolam Hydrochloride	Injection, solution	5 mg/mL	Intramuscular; Intravenous	Dispensing Solutions, Inc.	2011-05-02	Not applicable	US
Midazolam Hydrochloride	Injection, solution	1 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2000-06-20	Not applicable	US
Midazolam Hydrochloride	Injection	1 mg/mL	Intramuscular; Intravenous	Wockhardt	2008-11-10	Not applicable	US
Midazolam Hydrochloride	Injection	5 mg/mL	Intramuscular; Intravenous	Cardinal Health	2000-06-21	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Midazolam HCl	Injection, solution	.5 mg/mL	Intravenous	Cantrell Drug Company	2013-01-30	Not applicable	US
Midazolam HCl	Injection, solution	1 mg/mL	Intravenous	Cantrell Drug Company	2010-08-02	Not applicable	US

International Brands

Name	Company
Anquil	General Pharma
Benzosed	Pharmaceutical
Dalam	Richmond
Damizol	Specifar
Demizolam	Dem Ilaç
Doricum	Roche
Dormicum	Roche
Dormid	Scott
Dormipron	Chalver
Dormire	Cristália
Dormitol	Square
Dormixal	Demo
Dormonid	Roche
Drimnorth	Northia
Epistatus	IFET
Flormidal	Galenika
Fulsed	Ranbaxy
Fulsed Injection	Terapia
Garen	Bio-Pharma
Gobbizolam	Gobbi
Hipnazolam	EMS
Hipnoz	Pharos
Hypnofast	Incepta
Hypnovel	Roche
Ipnovel	Roche
Nocturna	Lafi
Setam	Rimsa
Talentum	Fisiopharma
Terap	Sanitas
Versed	Roche

Brand mixtures

Not Available

Categories

UNII

R60L0SM5BC

CAS number

59467-70-8

Weight

Average: 325.767
Monoisotopic: 325.078203343

Chemical Formula

C₁₈H₁₃ClFN₃

InChI Key

DDLIGBOFAVUZHB-UHFFFAOYSA-N

InChI

InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3

IUPAC Name

12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene

SMILES

CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12

Pharmacology

Indication

The midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia.

Structured Indications

Pharmacodynamics

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Mechanism of action

It is thought that the actions of benzodiazepines such as midazolam are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines increase the activity of GABA, thereby producing a calming effect, relaxing skeletal muscles, and inducing sleep. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1	Protein	yes	potentiator	Human	P14867	details
Gamma-aminobutyric acid receptor subunit alpha-2	Protein	yes	potentiator	Human	P47869	details
Gamma-aminobutyric acid receptor subunit alpha-3	Protein	yes	potentiator	Human	P34903	details
Gamma-aminobutyric acid receptor subunit alpha-4	Protein	yes	potentiator	Human	P48169	details
Gamma-aminobutyric acid receptor subunit alpha-5	Protein	yes	potentiator	Human	P31644	details
Gamma-aminobutyric acid receptor subunit beta-1	Protein	yes	potentiator	Human	P18505	details
Gamma-aminobutyric acid receptor subunit beta-3	Protein	yes	potentiator	Human	P28472	details
Gamma-aminobutyric acid receptor subunit beta-2	Protein	yes	potentiator	Human	P47870	details
Gamma-aminobutyric acid receptor subunit alpha-6	Protein	yes	potentiator	Human	Q16445	details
Gamma-aminobutyric acid receptor subunit gamma-1	Protein	yes	potentiator	Human	Q8N1C3	details
Gamma-aminobutyric acid receptor subunit gamma-2	Protein	yes	potentiator	Human	P18507	details
Gamma-aminobutyric acid receptor subunit gamma-3	Protein	yes	potentiator	Human	Q99928	details
Gamma-aminobutyric acid receptor subunit delta	Protein	yes	potentiator	Human	O14764	details
Gamma-aminobutyric acid receptor subunit epsilon	Protein	yes	potentiator	Human	P78334	details
Gamma-aminobutyric acid receptor subunit pi	Protein	yes	potentiator	Human	O00591	details
Gamma-aminobutyric acid receptor subunit rho-1	Protein	yes	potentiator	Human	P24046	details
Gamma-aminobutyric acid receptor subunit rho-2	Protein	yes	potentiator	Human	P28476	details
Gamma-aminobutyric acid receptor subunit rho-3	Protein	yes	potentiator	Human	A8MPY1	details
Gamma-aminobutyric acid receptor subunit theta	Protein	yes	potentiator	Human	Q9UN88	details

Absorption

Rapidly absorbed after oral administration. The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%. The absolute bioavailability, if given intramuscularly (IM), is greater than 90%. Cmax, IM = 90 ng/mL; Tmax, IM = 0.5 hours. Following IM administered, Cmax for midazolam and its 1-hydroxy metabolite were approxiately one-half of those achieved after intravenous injection.

Volume of distribution

1.24 to 2.02 L/kg [pediatric patients (6 months to <16 years) receiving 0.15 mg/kg IV midazolam,]
1 to 3.1 L/kg [intravenously administered, healthy adults] Female gender, old age, and obesity may increase the volume of distribution. Midazolam may also cross the placenta and has been detected in human milk and cerebrospinal fluid.

Protein binding

97% protein bound.

Metabolism

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam (also known as 1-hydroxy-midazolam), and 4-hydroxymidazolam (makes up 5% or less of the biotransformation products). 1-hydroxy-midazolam is at least as potent as the parent compound and may contributed to the overall activity of midazolam. In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. It also undergoes N-glucuronidation via UGT1A4.

Substrate	Enzymes	Product
Midazolam	Cytochrome P450 2B6 Cytochrome P450 3A4 Cytochrome P450 3A5 Cytochrome P450 3A7 Cytochrome P450 4B1	Alpha-hydroxymidazolam	Details
Midazolam	Cytochrome P450 3A5 Cytochrome P450 3A7 Cytochrome P450 4B1 Cytochrome P450 3A4	4-hydroxymidazolam	Details

Route of elimination

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, α-hydroxymidazolam, followed by glucuronidation of the α–hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The α- hydroxymidazolam glucuronide is then excreted in urine. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates. The amount of midazolam excreted unchanged in the urine when given intravenously is less than 0.5%. 45% to 57% of the dose was excreted in the urine as 1-hydroxymethyl midazolam conjugate.

Half life

Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)

Clearance

9.3 to 11 mL/min/kg [pediatric patients (6 months to <16 years old)]
0.25 to 0.54 L/hr/kg [intravenous, healthy adults]

Toxicity

LD₅₀=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.	Experimental
3,4-Dichloroisocoumarin	The serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.	Experimental
4-(2-Aminoethyl)Benzenesulfonyl Fluoride	The serum concentration of Midazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.	Experimental
7-Nitroindazole	The risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole.	Experimental
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Midazolam.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Midazolam.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Adipiplon	The risk or severity of adverse effects can be increased when Midazolam is combined with adipiplon.	Investigational
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Midazolam.	Approved
Agomelatine	The risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.	Approved, Investigational
Albendazole	The serum concentration of Midazolam can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Midazolam can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Midazolam can be increased when it is combined with Alectinib.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone.	Vet Approved
Alfentanil	The serum concentration of Midazolam can be increased when it is combined with Alfentanil.	Approved, Illicit
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Midazolam.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Midazolam is combined with Sage 547.	Investigational
Alogliptin	The serum concentration of Midazolam can be increased when it is combined with Alogliptin.	Approved
Alpha-1-proteinase inhibitor	The serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Midazolam is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.	Approved, Illicit, Investigational
Amantadine	The serum concentration of Midazolam can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Midazolam.	Approved, Investigational
Ambroxol acefyllinate	The therapeutic efficacy of Midazolam can be decreased when used in combination with Ambroxol acefyllinate.	Experimental
Aminohippuric acid	The serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid.	Approved
Aminophylline	The therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline.	Approved
Amiodarone	The metabolism of Midazolam can be decreased when combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.	Approved
Amlodipine	The serum concentration of Midazolam can be increased when it is combined with Amlodipine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide.	Experimental
Amprenavir	The serum concentration of Midazolam can be increased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Midazolam can be increased when it is combined with Amsacrine.	Approved
Antithrombin III human	The serum concentration of Midazolam can be increased when it is combined with Antithrombin III human.	Approved
Apixaban	The serum concentration of Midazolam can be increased when it is combined with Apixaban.	Approved
Aprepitant	The serum concentration of Midazolam can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprotinin	The serum concentration of Midazolam can be increased when it is combined with Aprotinin.	Approved, Withdrawn
Argatroban	The serum concentration of Midazolam can be increased when it is combined with Argatroban.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine.	Approved
Astemizole	The serum concentration of Midazolam can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Midazolam can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Midazolam.	Approved
Atomoxetine	The metabolism of Midazolam can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Midazolam can be increased when it is combined with Atorvastatin.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Midazolam.	Approved, Investigational
Azelastine	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The serum concentration of Midazolam can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Midazolam can be increased when it is combined with Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Midazolam is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.	Illicit
Batimastat	The serum concentration of Midazolam can be increased when it is combined with Batimastat.	Experimental
Benazepril	The serum concentration of Midazolam can be increased when it is combined with Benazepril.	Approved, Investigational
Benperidol	The risk or severity of adverse effects can be increased when Midazolam is combined with Benperidol.	Investigational
Benzamidine	The serum concentration of Midazolam can be increased when it is combined with Benzamidine.	Experimental
Benzocaine	The serum concentration of Midazolam can be increased when it is combined with Benzocaine.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol.	Approved
Bepridil	The serum concentration of Midazolam can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Bexarotene	The serum concentration of Midazolam can be decreased when it is combined with Bexarotene.	Approved, Investigational
Biperiden	The serum concentration of Midazolam can be increased when it is combined with Biperiden.	Approved
Bivalirudin	The serum concentration of Midazolam can be increased when it is combined with Bivalirudin.	Approved, Investigational
Boceprevir	The serum concentration of Midazolam can be increased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Midazolam can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Midazolam can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Midazolam.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.	Approved, Illicit
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.	Approved, Investigational
Buprenorphine	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Midazolam can be increased when it is combined with Buspirone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Midazolam is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.	Approved, Illicit, Vet Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Midazolam.	Approved
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Midazolam.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.	Approved
Candesartan	The serum concentration of Midazolam can be increased when it is combined with Candesartan.	Approved
Candoxatril	The serum concentration of Midazolam can be increased when it is combined with Candoxatril.	Experimental
Candoxatrilat	The serum concentration of Midazolam can be increased when it is combined with Candoxatrilat.	Experimental
Captopril	The serum concentration of Midazolam can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Midazolam can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Midazolam is combined with Carfentanil.	Illicit, Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Midazolam.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.	Approved
Carvedilol	The serum concentration of Midazolam can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Midazolam can be increased when it is combined with Caspofungin.	Approved
Ceritinib	The serum concentration of Midazolam can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Midazolam.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Midazolam is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.	Approved
Chloroquine	The serum concentration of Midazolam can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.	Approved
Cholesterol	The serum concentration of Midazolam can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Midazolam can be decreased when it is combined with Cholic Acid.	Approved
Chymostatin	The serum concentration of Midazolam can be increased when it is combined with Chymostatin.	Experimental
Cilastatin	The serum concentration of Midazolam can be increased when it is combined with Cilastatin.	Approved
Cilazapril	The serum concentration of Midazolam can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Midazolam can be decreased when it is combined with Cimetidine.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Midazolam.	Approved, Vet Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam.	Approved, Investigational
Cisplatin	The serum concentration of Cisplatin can be decreased when it is combined with Midazolam.	Approved
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Midazolam.	Approved
Clarithromycin	The serum concentration of Midazolam can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Midazolam can be decreased when combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.	Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Midazolam.	Approved, Illicit
Clofazimine	The serum concentration of Midazolam can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Midazolam.	Approved, Investigational
Clomipramine	The serum concentration of Midazolam can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Midazolam.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.	Approved, Nutraceutical
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.	Approved, Illicit
Clotrimazole	The metabolism of Midazolam can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Midazolam is combined with Clozapine.	Approved
Cobicistat	The serum concentration of Midazolam can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Midazolam.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Midazolam.	Approved
Colforsin	The serum concentration of Midazolam can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Midazolam can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Midazolam.	Approved
Crizotinib	The metabolism of Midazolam can be decreased when combined with Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.	Approved
Cyclophosphamide	The serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The metabolism of Midazolam can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.	Approved
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.	Approved
Dabrafenib	The serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Midazolam can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be decreased when it is combined with Midazolam.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.	Investigational
Darexaban	The serum concentration of Midazolam can be increased when it is combined with Ym150.	Investigational
Darunavir	The serum concentration of Midazolam can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Midazolam can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Midazolam.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Midazolam.	Approved
Deferasirox	The serum concentration of Midazolam can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Midazolam can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Midazolam is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.	Approved
Desipramine	The serum concentration of Midazolam can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Midazolam can be increased when it is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.	Approved
Dexamethasone	The serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam.	Approved, Vet Approved
Dextromethorphan	The serum concentration of Midazolam can be increased when it is combined with Dextromethorphan.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dezocine.	Approved
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Midazolam.	Approved, Illicit, Vet Approved
Diclofenac	The serum concentration of Midazolam can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Midazolam is combined with Difenoxin.	Approved, Illicit
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Midazolam.	Approved
Digoxin	The serum concentration of Midazolam can be decreased when it is combined with Digoxin.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The metabolism of Midazolam can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.	Experimental, Illicit
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam.	Illicit
Diltiazem	The metabolism of Midazolam can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.	Approved
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Midazolam.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Midazolam.	Approved, Investigational, Vet Approved
Doxazosin	The serum concentration of Midazolam can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Midazolam can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Midazolam.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Midazolam.	Approved, Investigational
Doxycycline	The metabolism of Midazolam can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Illicit
Dronedarone	The metabolism of Midazolam can be decreased when combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Midazolam is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.	Approved
Dyphylline	The therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.	Approved
Ecabet	The serum concentration of Midazolam can be increased when it is combined with Ecabet.	Approved, Investigational
Ecgonine	The risk or severity of adverse effects can be increased when Midazolam is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam.	Investigational
Edoxaban	The serum concentration of Midazolam can be increased when it is combined with Edoxaban.	Approved
Efavirenz	The serum concentration of Midazolam can be decreased when it is combined with Efavirenz.	Approved, Investigational
Elafin	The serum concentration of Midazolam can be increased when it is combined with Elafin.	Investigational
Elbasvir	The serum concentration of Midazolam can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Midazolam.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Midazolam is combined with Pregnanolone.	Investigational
Enalapril	The serum concentration of Midazolam can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The serum concentration of Midazolam can be increased when it is combined with Enalaprilat.	Approved
Enalkiren	The serum concentration of Midazolam can be increased when it is combined with Enalkiren.	Experimental
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Midazolam.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Midazolam.	Approved, Investigational
Ergonovine	The serum concentration of Midazolam can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Midazolam can be increased when it is combined with Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Midazolam.	Approved, Investigational
Erythromycin	The serum concentration of Midazolam can be increased when it is combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Midazolam can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Midazolam.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Midazolam can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Midazolam.	Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.	Approved
Ethanol	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Midazolam is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone.	Approved
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Midazolam.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Midazolam can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Midazolam.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Midazolam.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Midazolam is combined with Ezogabine.	Approved
Faldaprevir	The serum concentration of Midazolam can be increased when it is combined with Bi201335.	Investigational
Felbamate	The risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.	Approved
Felodipine	The serum concentration of Midazolam can be increased when it is combined with Felodipine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The serum concentration of Midazolam can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Midazolam.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Midazolam.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.	Approved
Fluconazole	The metabolism of Midazolam can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The serum concentration of Midazolam can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Midazolam can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Midazolam can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Midazolam can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The metabolism of Midazolam can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The serum concentration of Midazolam can be increased when it is combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Midazolam can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The serum concentration of Midazolam can be increased when it is combined with Fosinopril.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Midazolam.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol.	Approved, Illicit
Fusidic Acid	The serum concentration of Midazolam can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Midazolam is combined with gabapentin enacarbil.	Approved
Gabexate	The serum concentration of Midazolam can be increased when it is combined with Gabexate.	Investigational
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Midazolam is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Midazolam.	Approved, Investigational
Geldanamycin	The serum concentration of Midazolam can be increased when it is combined with Geldanamycin.	Experimental
Gemcitabine	The serum concentration of Gemcitabine can be decreased when it is combined with Midazolam.	Approved
Genistein	The serum concentration of Midazolam can be increased when it is combined with Genistein.	Investigational
Gepirone	The risk or severity of adverse effects can be increased when Midazolam is combined with Gepirone.	Investigational
Ginkgo biloba	The serum concentration of Midazolam can be decreased when it is combined with Ginkgo biloba.	Approved, Nutraceutical
Glutethimide	The risk or severity of adverse effects can be increased when Midazolam is combined with Glutethimide.	Approved, Illicit
Glyburide	The serum concentration of Midazolam can be increased when it is combined with Glyburide.	Approved
GM6001	The serum concentration of Midazolam can be increased when it is combined with GM6001.	Experimental
Gramicidin D	The serum concentration of Midazolam can be increased when it is combined with Gramicidin D.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Midazolam.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam.	Withdrawn
Guanfacine	The risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Midazolam.	Approved
Halothane	The risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Midazolam is combined with Heroin.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.	Approved
Hyaluronidase	The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.	Approved, Investigational
Hydrocodone	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Midazolam.	Approved
Idelalisib	The serum concentration of Midazolam can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.	Approved
Imatinib	The metabolism of Midazolam can be decreased when combined with Imatinib.	Approved
Imidapril	The serum concentration of Midazolam can be increased when it is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Midazolam.	Approved
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Midazolam.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.	Investigational, Withdrawn
Indinavir	The serum concentration of Midazolam can be increased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Midazolam.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Midazolam.	Approved, Investigational
Isavuconazonium	The metabolism of Midazolam can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurane	The risk or severity of adverse effects can be increased when Midazolam is combined with Isoflurane.	Approved, Vet Approved
Isoflurophate	The serum concentration of Midazolam can be increased when it is combined with Isoflurophate.	Approved, Withdrawn
Isradipine	The metabolism of Midazolam can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Midazolam can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Midazolam can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Ixazomib	The serum concentration of Midazolam can be increased when it is combined with Ixazomib.	Approved
Josamycin	The serum concentration of Midazolam can be increased when it is combined with Josamycin.	Approved
Ketamine	The serum concentration of Midazolam can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Midazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.	Approved
Ketoconazole	The serum concentration of Midazolam can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoconazole	The metabolism of Midazolam can be decreased when combined with Ketoconazole.	Approved, Investigational
Kitasamycin	The serum concentration of Midazolam can be increased when it is combined with Kitasamycin.	Experimental
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Midazolam.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Midazolam.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Midazolam.	Approved, Investigational
Lapatinib	The serum concentration of Midazolam can be increased when it is combined with Lapatinib.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Midazolam.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Midazolam.	Approved
Lepirudin	The serum concentration of Midazolam can be increased when it is combined with Lepirudin.	Approved
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Midazolam is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Midazolam.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.	Approved
Levothyroxine	The serum concentration of Midazolam can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Midazolam can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Midazolam can be increased when it is combined with Linagliptin.	Approved
Liothyronine	The serum concentration of Midazolam can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Midazolam can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Midazolam can be increased when it is combined with Lisinopril.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Midazolam is combined with Lofentanil.	Illicit
Lomitapide	The serum concentration of Midazolam can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Midazolam.	Approved
Lopinavir	The serum concentration of Midazolam can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Midazolam can be increased when it is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Midazolam.	Approved
Lovastatin	The metabolism of Midazolam can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.	Approved
Luliconazole	The serum concentration of Midazolam can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Midazolam can be decreased when it is combined with Lumacaftor.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Vet Approved
Mannitol	The serum concentration of Mannitol can be decreased when it is combined with Midazolam.	Approved, Investigational
Maprotiline	The serum concentration of Midazolam can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Midazolam can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Meclizine	The risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine.	Approved
Mefloquine	The serum concentration of Midazolam can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Midazolam can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Midazolam is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Midazolam is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The serum concentration of Midazolam can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.	Approved
Methadone	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Midazolam is combined with Methadyl Acetate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.	Approved
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Midazolam.	Approved
Methotrimeprazine	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Midazolam is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Metoprolol	The serum concentration of Metoprolol can be decreased when it is combined with Midazolam.	Approved, Investigational
Metyrosine	Midazolam may increase the sedative activities of Metyrosine.	Approved
Mibefradil	The serum concentration of Midazolam can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Midazolam can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Mifepristone	The serum concentration of Midazolam can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Midazolam.	Approved
Mirtazapine	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitomycin	The serum concentration of Midazolam can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Midazolam can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam.	Approved, Investigational
Modafinil	The serum concentration of Midazolam can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The serum concentration of Midazolam can be increased when it is combined with Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.	Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Midazolam.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.	Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	The serum concentration of Midazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Midazolam.	Approved
Nafamostat	The serum concentration of Midazolam can be increased when it is combined with Nafamostat.	Approved, Investigational
Nafcillin	The serum concentration of Midazolam can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Midazolam.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Naltrexone	The serum concentration of Midazolam can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Midazolam can be increased when it is combined with Naringenin.	Experimental
NCX 4016	The serum concentration of Midazolam can be increased when it is combined with NCX 4016.	Investigational
Nefazodone	The metabolism of Midazolam can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Midazolam can be increased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Midazolam can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Midazolam can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Midazolam can be increased when combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Midazolam.	Approved
Nifedipine	The serum concentration of Midazolam can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The metabolism of Midazolam can be decreased when combined with Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Midazolam.	Approved
Nisoldipine	The serum concentration of Midazolam can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Midazolam can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Midazolam can be increased when it is combined with Nitrendipine.	Approved
Nitroaspirin	The serum concentration of Midazolam can be increased when it is combined with Nitroaspirin.	Investigational
Nitrous oxide	The risk or severity of adverse effects can be increased when Midazolam is combined with Nitrous oxide.	Approved, Vet Approved
Nizatidine	The serum concentration of Nizatidine can be decreased when it is combined with Midazolam.	Approved
Norethisterone	The serum concentration of Midazolam can be decreased when it is combined with Norethisterone.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Midazolam is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Midazolam is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.	Approved, Investigational
Olaparib	The metabolism of Midazolam can be decreased when combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.	Approved
Omapatrilat	The serum concentration of Midazolam can be increased when it is combined with Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be decreased when it is combined with Midazolam.	Approved
Omeprazole	The serum concentration of Midazolam can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Midazolam is combined with Opium.	Approved, Illicit
Orphenadrine	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Midazolam can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.	Approved, Investigational, Vet Approved
P-Nitrophenol	The serum concentration of Midazolam can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Palbociclib	The serum concentration of Midazolam can be increased when it is combined with Palbociclib.	Approved
Paliperidone	The risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.	Approved
Palmitic Acid	The serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.	Experimental
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Midazolam.	Approved, Investigational
Pantoprazole	The serum concentration of Midazolam can be increased when it is combined with Pantoprazole.	Approved
Paraldehyde	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The serum concentration of Midazolam can be increased when it is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Midazolam.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.	Approved, Vet Approved
Pentobarbital	The metabolism of Midazolam can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved
Perazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Perazine.	Investigational
Perindopril	The serum concentration of Midazolam can be increased when it is combined with Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.	Approved
Phenobarbital	The metabolism of Midazolam can be increased when combined with Phenobarbital.	Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Midazolam.	Approved, Vet Approved
Phosphoramidon	The serum concentration of Midazolam can be increased when it is combined with Phosphoramidon.	Experimental
Pimozide	The serum concentration of Midazolam can be increased when it is combined with Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Midazolam is combined with Piritramide.	Investigational
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Midazolam.	Approved
Platelet Activating Factor	The serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.	Experimental
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Midazolam.	Approved
Posaconazole	The metabolism of Midazolam can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	Midazolam may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Midazolam.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.	Approved, Illicit
Prazosin	The serum concentration of Prazosin can be decreased when it is combined with Midazolam.	Approved
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Prilocaine.	Approved
Primidone	The metabolism of Midazolam can be increased when combined with Primidone.	Approved, Vet Approved
Prinomastat	The serum concentration of Midazolam can be increased when it is combined with Prinomastat.	Investigational
Probenecid	The serum concentration of Midazolam can be increased when it is combined with Probenecid.	Approved
Procaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Procaine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.	Approved, Vet Approved
Progesterone	The serum concentration of Midazolam can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.	Approved, Vet Approved
Promethazine	The serum concentration of Midazolam can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Midazolam can be increased when it is combined with Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.	Approved, Vet Approved
Propofol	The serum concentration of Propofol can be increased when it is combined with Midazolam.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Propoxycaine.	Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Midazolam.	Approved, Investigational
Protriptyline	The serum concentration of Midazolam can be increased when it is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Midazolam.	Approved
Quazepam	The serum concentration of Midazolam can be increased when it is combined with Quazepam.	Approved, Illicit
Quercetin	The serum concentration of Midazolam can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Midazolam.	Approved
Quinacrine	The serum concentration of Midazolam can be increased when it is combined with Quinacrine.	Approved
Quinapril	The serum concentration of Midazolam can be increased when it is combined with Quinapril.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Midazolam.	Approved
Quinine	The serum concentration of Quinine can be decreased when it is combined with Midazolam.	Approved
Racecadotril	The serum concentration of Midazolam can be increased when it is combined with Racecadotril.	Investigational
Raclopride	The risk or severity of adverse effects can be increased when Midazolam is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.	Approved, Investigational
Ramipril	The serum concentration of Midazolam can be increased when it is combined with Ramipril.	Approved
Ranitidine	The serum concentration of Ranitidine can be decreased when it is combined with Midazolam.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Midazolam.	Approved, Investigational
Reboxetine	The serum concentration of Midazolam can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Midazolam can be increased when it is combined with Regorafenib.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.	Approved
Remikiren	The serum concentration of Midazolam can be increased when it is combined with Remikiren.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam.	Approved, Withdrawn
Reserpine	The serum concentration of Midazolam can be decreased when it is combined with Reserpine.	Approved
Rifabutin	The metabolism of Midazolam can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Midazolam can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Midazolam can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Midazolam.	Approved, Investigational
Rilpivirine	The serum concentration of Midazolam can be increased when it is combined with Rilpivirine.	Approved
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Midazolam.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Midazolam is combined with Ritanserin.	Investigational
Ritonavir	The serum concentration of Midazolam can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.	Approved
Rolapitant	The serum concentration of Midazolam can be increased when it is combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Midazolam.	Approved, Investigational
Ropinirole	Midazolam may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam.	Approved
Rotigotine	Midazolam may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Midazolam.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be decreased when it is combined with Midazolam.	Approved, Vet Approved
Saquinavir	The serum concentration of Midazolam can be increased when it is combined with Saquinavir.	Approved, Investigational
Saxagliptin	The serum concentration of Midazolam can be increased when it is combined with Saxagliptin.	Approved
Scopolamine	The serum concentration of Midazolam can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.	Approved, Vet Approved
Selegiline	The serum concentration of Midazolam can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Midazolam.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Midazolam is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole.	Approved, Withdrawn
Sertraline	The serum concentration of Midazolam can be increased when it is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The metabolism of Midazolam can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Midazolam.	Approved
Siltuximab	The serum concentration of Midazolam can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Midazolam can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Midazolam can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Midazolam can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitagliptin	The serum concentration of Midazolam can be increased when it is combined with Sitagliptin.	Approved, Investigational
Sodium oxybate	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Midazolam.	Approved
Solithromycin	The serum concentration of Midazolam can be increased when it is combined with Solithromycin.	Investigational
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Midazolam.	Approved, Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Midazolam.	Experimental
Spirapril	The serum concentration of Midazolam can be increased when it is combined with Spirapril.	Approved
Spironolactone	The serum concentration of Midazolam can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Midazolam can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Midazolam can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Midazolam can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Midazolam can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.	Approved, Investigational
Sulfinpyrazone	The serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Midazolam can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam.	Approved
Sumatriptan	The serum concentration of Midazolam can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Midazolam can be increased when it is combined with Sunitinib.	Approved, Investigational
Suvorexant	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tacrine	The serum concentration of Midazolam can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Midazolam can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Midazolam.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Midazolam is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Midazolam is combined with Tasimelteon.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Midazolam.	Approved
Teduglutide	The serum concentration of Midazolam can be increased when it is combined with Teduglutide.	Approved
Telaprevir	The serum concentration of Midazolam can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of Midazolam can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Midazolam can be increased when it is combined with Telmisartan.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.	Approved
Temocapril	The serum concentration of Midazolam can be increased when it is combined with Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.	Approved
Terazosin	The serum concentration of Midazolam can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Midazolam can be increased when it is combined with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Midazolam can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Midazolam can be increased when it is combined with Testosterone.	Approved, Investigational
Tetrabenazine	The risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin.	Investigational
Thalidomide	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Midazolam.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.	Withdrawn
Thiorphan	The serum concentration of Midazolam can be increased when it is combined with Thiorphan.	Experimental
Thiotepa	The metabolism of Midazolam can be decreased when combined with Thiotepa.	Approved
Thiothixene	The risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.	Approved
Ticlopidine	The metabolism of Midazolam can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be decreased when it is combined with Midazolam.	Approved
Tipranavir	The serum concentration of Midazolam can be increased when it is combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.	Approved
Tocilizumab	The serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.	Approved, Withdrawn
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Midazolam.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Midazolam.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Midazolam.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.	Approved, Investigational
Trandolapril	The serum concentration of Midazolam can be increased when it is combined with Trandolapril.	Approved
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Midazolam.	Approved
Trazodone	The serum concentration of Midazolam can be decreased when it is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.	Approved
Trifluoperazine	The serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Midazolam can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Midazolam can be increased when it is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.	Approved
Ubenimex	The serum concentration of Midazolam can be increased when it is combined with Ubenimex.	Experimental
Ulinastatin	The serum concentration of Midazolam can be increased when it is combined with Ulinastatin.	Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Midazolam.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Midazolam.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Midazolam.	Approved, Investigational
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Midazolam.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Midazolam.	Approved
Venlafaxine	The metabolism of Midazolam can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Midazolam can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin.	Approved
Vildagliptin	The serum concentration of Midazolam can be increased when it is combined with Vildagliptin.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Midazolam.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Midazolam.	Approved, Investigational
Vinorelbine	The serum concentration of Midazolam can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Midazolam.	Approved
Voriconazole	The metabolism of Midazolam can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.	Approved
Ximelagatran	The serum concentration of Midazolam can be increased when it is combined with Ximelagatran.	Approved, Investigational, Withdrawn
Yohimbine	The therapeutic efficacy of Midazolam can be decreased when used in combination with Yohimbine.	Approved, Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Midazolam.	Approved
Zimelidine	The serum concentration of Midazolam can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Midazolam can be decreased when combined with Ziprasidone.	Approved
Zolpidem	Midazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Midazolam is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Midazolam is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Grapefruit juice slows the product's absorption and significantly increases its bioavailability.

References

Synthesis Reference

Madhup K. Dhaon, "Process for the preparation of midazolam." U.S. Patent US6262260, issued August, 1979.

US6262260

General References

Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]
Isojarvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:80-92. [PubMed:10030438 ]
Garratt JC, Gent JP, Feely M, Haigh JR: Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential? Eur J Pharmacol. 1988 Jan 5;145(1):75-80. [PubMed:2894998 ]
Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14821
KEGG Drug	D00550
KEGG Compound	C07524
PubChem Compound	4192
PubChem Substance	46507611
ChemSpider	4047
BindingDB	21363
ChEBI	6931
ChEMBL	CHEMBL655
Therapeutic Targets Database	DAP000241
PharmGKB	PA450496
IUPHAR	3342
Guide to Pharmacology	3342
HET	08J
Drug Product Database	11188
RxList	http://www.rxlist.com/cgi/generic2/versedsyr.htm
Drugs.com	http://www.drugs.com/cdi/midazolam.html
Wikipedia	Midazolam

ATC Codes

N05CD08 — Midazolam

AHFS Codes

28:24.08

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (73.7 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Prevention	Depressive State	1
0	Completed	Treatment	Anxiety Disease	1
0	Completed	Treatment	Bipolar I Disorder / Bipolar II Disorder / Depression, Bipolar / Major Depressive Disorder (MDD) / Suicidal Ideation	1
0	Not Yet Recruiting	Treatment	Midazolam Overdose	1
0	Not Yet Recruiting	Treatment	Sedation, Conscious	1
0	Recruiting	Treatment	Cancers / Ketamine / Tiredness	1
1	Active Not Recruiting	Not Available	AAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver	1
1	Active Not Recruiting	Basic Science	Healthy Participants	1
1	Active Not Recruiting	Basic Science	Moderate to Severe Plaque Psoriasis	1
1	Active Not Recruiting	Basic Science	Nash	1
1	Active Not Recruiting	Other	Drug Interactions / Healthy Volunteers	1
1	Active Not Recruiting	Other	Healthy Volunteers	1
1	Active Not Recruiting	Other	Neoplasms	1
1	Active Not Recruiting	Treatment	Advanced Non-Central Nervous System (CNS) Malignancies	1
1	Active Not Recruiting	Treatment	Cancer, Ovarian / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Head and Neck Carcinoma / Islet Cell Tumor / Lung Cancers / Metastatic Cancers / Neuroendocrine Carcinoma of the Skin / Pheochromocytomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Active Not Recruiting	Treatment	Epidermal Growth Factor Receptor Mutations / Non-Small-Cell Lung Cancer (NSCLC)	1
1	Active Not Recruiting	Treatment	Influenza in Humans	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1	Active Not Recruiting	Treatment	Neoplasms	1
1	Active Not Recruiting	Treatment	Pharmacokinetics / Voriconazole	1
1	Active Not Recruiting	Treatment	Psoriasis	1
1	Active Not Recruiting	Treatment	Tumors	1
1	Active Not Recruiting	Treatment	CMET-dysregulated Advanced Solid Tumors	1
1	Completed	Not Available	Chronic Hepatitis C Infection	1
1	Completed	Not Available	HIV-infection/AIDS	1
1	Completed	Not Available	Healthy Volunteers	10
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of ASP015K and Midazolam	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Midazolam	1
1	Completed	Not Available	Pain, Chronic	1
1	Completed	Not Available	Pharmacokinetic Interactions	1
1	Completed	Not Available	Schizophrenia Patients	1
1	Completed	Not Available	Tumors, Solid	1
1	Completed	Basic Science	Alzheimer's Disease (AD) / Metabolism	1
1	Completed	Basic Science	Diabetes Mellitus (DM) / Glucose Metabolism Disorders / Type 2 Diabetes Mellitus	1
1	Completed	Basic Science	Drug Biotransformation / Membrane Transport	1
1	Completed	Basic Science	Drug Interactions	1
1	Completed	Basic Science	Endometriosis	1
1	Completed	Basic Science	Genotype-related Drug Metabolism	1
1	Completed	Basic Science	Healthy Adult Subjects and Healthy Elderly Subjects	1
1	Completed	Basic Science	Healthy Adult Volunteers	1
1	Completed	Basic Science	Healthy Male Volunteers	1
1	Completed	Basic Science	Healthy Volunteers	14
1	Completed	Basic Science	Healthy Volunteers / Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Basic Science	Healthy Volunteers / Pharmacologic Actions	1
1	Completed	Basic Science	Pharmacokinetic Assessments in Healthy Volunteers	1
1	Completed	Basic Science	Rheumatoid Arthritis	3
1	Completed	Basic Science	Type 2 Diabetes Mellitus	1
1	Completed	Basic Science	VA Drug Interactions / VA Drug Interactions [VA Drug Interaction]	1
1	Completed	Basic Science	Moderate, refractory Atopic dermatitis	1
1	Completed	Diagnostic	Cytochrome / Pharmacokinetics	1
1	Completed	Diagnostic	Digestive System Disorders	1
1	Completed	Diagnostic	Drug Interactions	1
1	Completed	Diagnostic	Healthy Volunteers	2
1	Completed	Health Services Research	Healthy Volunteers	1
1	Completed	Other	Healthy Volunteers	1
1	Completed	Treatment	Acute Myocardial Infarction (AMI) / Pain	1
1	Completed	Treatment	Adult Solid Neoplasm	1
1	Completed	Treatment	Advanced Solid Tumors, Excluding Breast Cancer	1
1	Completed	Treatment	Amnesia-Memory Loss / Memory Losses	1
1	Completed	Treatment	Anemias / Healthy Volunteers	1
1	Completed	Treatment	Atherosclerosis	1
1	Completed	Treatment	Cancers	1
1	Completed	Treatment	Carcinoma NOS / Hodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Neoplasms / Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Castration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV3100	1
1	Completed	Treatment	Drug Interaction Potentiation	1
1	Completed	Treatment	Drug Interactions	2
1	Completed	Treatment	Healthy Male Volunteers	1
1	Completed	Treatment	Healthy Volunteers	22
1	Completed	Treatment	Heart Failure, Unspecified	1
1	Completed	Treatment	Hepatitis C, Chronic	1
1	Completed	Treatment	Infections, Bacterial / Pneumonia / Skin Diseases, Infectious	1
1	Completed	Treatment	Infectious Diseases	1
1	Completed	Treatment	Japanese Healthy Adult Males	1
1	Completed	Treatment	Low Back Pain (LBP)	1
1	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	1
1	Completed	Treatment	Prophylaxis against postoperative nausea and vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting	1
1	Completed	Treatment	Psoriasis	1
1	Completed	Treatment	Relapsed or Refractory Advanced Cancer	1
1	Completed	Treatment	Schizophrenia or Schizoaffective Disorder	1
1	Completed	Treatment	Seizures	1
1	Completed	Treatment	Skin Diseases, Bacterial	1
1	Completed	Treatment	Tuberculosis	1
1	Completed	Treatment	Tuberculosis / Tuberculosis, Pulmonary	1
1	Completed	Treatment	Tumors, Solid	2
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Not Yet Recruiting	Treatment	Hepatitis B,Chronic	1
1	Not Yet Recruiting	Treatment	Tuberculosis / Tuberculosis, Pulmonary	1
1	Recruiting	Basic Science	Healthy Volunteers	1
1	Recruiting	Basic Science	Neoplasms Metastasis	1
1	Recruiting	Other	ALK-positive Advanced Tumors	1
1	Recruiting	Other	Depressive State / Major Depressive Disorder (MDD) / Recurrent Depressive Disorder / Relapses	1
1	Recruiting	Other	Healthy Volunteers	2
1	Recruiting	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
1	Recruiting	Treatment	Cancer, Advanced / Colorectal Cancers / Metastatic Melanoma / Metastatic Non-Small Cell Lung Cancer / Metastatic Pancreatic Ductal Adenocarcinoma	1
1	Recruiting	Treatment	Cancer, Advanced / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Recruiting	Treatment	DRUG REACTIONS	1
1	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL) / Non-Hodgkin's Lymphoma, Solid Cancers / Solid Cancers	1
1	Terminated	Basic Science	Cancer, Advanced	1
1	Terminated	Other	Healthy Volunteers	2
1	Terminated	Other	Psoriasis Vulgaris	1
1	Terminated	Treatment	Cervical Pain	1
1	Terminated	Treatment	Epilepsies	1
1	Terminated	Treatment	Healthy Volunteers	1
1	Unknown Status	Basic Science	Healthy Volunteers	1
1	Unknown Status	Treatment	Healthy Volunteers	1
1	Withdrawn	Treatment	Healthy Volunteers	2
1, 2	Active Not Recruiting	Treatment	Bipolar Disorder (BD) / Major Depressive Episode / Suicidal Ideation	1
1, 2	Completed	Prevention	Post Operative Pain	1
1, 2	Completed	Treatment	Shock, Septic	1
1, 2	Recruiting	Treatment	Dependence, Cocaine	1
1, 2	Terminated	Prevention	Sepsis	1
1, 2	Terminated	Treatment	Obsessive Compulsive Disorder (OCD)	1
2	Active Not Recruiting	Treatment	Obsessive-Compulsive Disorder (OCD)	1
2	Completed	Supportive Care	Children	1
2	Completed	Supportive Care	Dental Anxiety	1
2	Completed	Treatment	Children Requiring Sedation to Facilitate Laceration Repair	1
2	Completed	Treatment	Endoscopy / Procedural Sedation	1
2	Completed	Treatment	Major Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)	1
2	Completed	Treatment	Seizures	1
2	Completed	Treatment	Treatment Resistant Depression (TRD)	1
2	Not Yet Recruiting	Prevention	Sedation During Spinal Anesthesia	1
2	Not Yet Recruiting	Treatment	Major Depressive Disorder (MDD)	1
2	Not Yet Recruiting	Treatment	Major Depressive Episode	1
2	Recruiting	Diagnostic	Delayed Recovery From Anaesthesia	1
2	Recruiting	Prevention	Forearm Surgeries	1
2	Recruiting	Supportive Care	Cancer of Breast / Cancer, Breast / Malignant Neoplasm of Female Breast	1
2	Recruiting	Treatment	Bipolar Disorder (BD)	1
2	Recruiting	Treatment	Major depressive disorder, recurrent episode	1
2	Recruiting	Treatment	Obsessive-Compulsive Disorder (OCD)	1
2	Recruiting	Treatment	Pain	1
2	Recruiting	Treatment	Posttraumatic Stress Disorders	1
2	Recruiting	Treatment	Subarachnoid Haemorrhage (SAH)	1
2	Terminated	Treatment	Feeling Anxious / Pain	1
2	Unknown Status	Prevention	Adenoidectomy / Otorhinolaryngologic Surgical Procedures / Postoperative Care / Postoperative pain / Surgical Procedures, Operative / Tonsillectomy	1
2	Unknown Status	Supportive Care	Intracranial Hemorrhages / Ischemia, Brain / Strokes / Vasospasm, Intracranial	1
2	Unknown Status	Treatment	Anxiety Disorder / Depressive State / PTSD / Stress Disorders, Post-Traumatic	1
2	Unknown Status	Treatment	Post Dural Puncture Headache	1
2	Withdrawn	Diagnostic	Computerized tomography / Procedural Sedation / Traumatic Brain Injury (TBI)	1
2	Withdrawn	Supportive Care	Delirium / Dyspnea / Nausea / Pain Intractable	1
2, 3	Completed	Prevention	Diagnostic Esophagogastroduodenoscopy	1
2, 3	Completed	Treatment	Anaesthesia therapy	1
2, 3	Completed	Treatment	Analgesia, Patient-Controlled / Spinal Stenosis	1
2, 3	Completed	Treatment	Chronic Otitis Media	1
2, 3	Completed	Treatment	Colonoscopy / Colorectal Polyps	1
2, 3	Completed	Treatment	Critical Illness	1
2, 3	Completed	Treatment	Dental Anxiety / Impacted Third Molar Tooth	1
2, 3	Completed	Treatment	Sedation therapy	1
2, 3	Recruiting	Treatment	Feeling Anxious / Postoperative pain / Prophylaxis against postoperative nausea and vomiting	1
2, 3	Recruiting	Treatment	Major depressive disorder, recurrent episode	1
2, 3	Recruiting	Treatment	Posttraumatic Stress Disorder (PTSD)	1
2, 3	Withdrawn	Treatment	PTSD	1
3	Completed	Not Available	Chronic Renal Failure (CRF) / Hip Fractures	1
3	Completed	Diagnostic	Cancer, Breast	1
3	Completed	Prevention	Hypertensive	1
3	Completed	Prevention	Post-operative Pain for Total Knee Arthroplasty	1
3	Completed	Supportive Care	Colonoscopy	1
3	Completed	Supportive Care	Epilepsies / Hydrocephaly	1
3	Completed	Treatment	Acute Traumatic Pain	1
3	Completed	Treatment	Anaesthesia therapy	1
3	Completed	Treatment	Child's Anxiety / Parental/Caregiver Anxiety	1
3	Completed	Treatment	Colonoscopy	1
3	Completed	Treatment	Continuous Sedation in Initially Sedated Adults in ICU	1
3	Completed	Treatment	Dental Anxiety	1
3	Completed	Treatment	Fracture Bone	1
3	Completed	Treatment	Paediatric Outpatient Surgery	1
3	Completed	Treatment	Sedation therapy	1
3	Not Yet Recruiting	Prevention	Emergence Delirium	1
3	Not Yet Recruiting	Treatment	Breech Presentation	1
3	Recruiting	Supportive Care	Fluoride Poisoning / Hepatic Function / Poisoning by Inhaled Anaesthetic / Recovery From Sedation / Renal Function	1
3	Recruiting	Treatment	Anxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders	1
3	Recruiting	Treatment	Bronchoscopy	1
3	Recruiting	Treatment	Feeling Anxious / Peripheral Nerve Blocks	1
3	Recruiting	Treatment	Inguinal Hernias / Local Anesthesia / Sedation, Conscious	1
3	Recruiting	Treatment	Sedation in Intensive Care	1
3	Recruiting	Treatment	Treatment Resistant Depressive Disorder	1
3	Terminated	Treatment	Acute Agitated Patients	1
3	Terminated	Treatment	Epilepsies	1
3	Terminated	Treatment	Traumatic Brain Injury (TBI)	1
3	Unknown Status	Supportive Care	Sedation therapy	1
3	Unknown Status	Treatment	Intubation Complications	1
4	Active Not Recruiting	Supportive Care	Epilepsies / Metabolic Diseases / Traumas	1
4	Active Not Recruiting	Supportive Care	Feeling Anxious / Laceration	1
4	Active Not Recruiting	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Critical Illness / Sleep	1
4	Active Not Recruiting	Treatment	Child Behavior / Dental Decay	1
4	Active Not Recruiting	Treatment	Complications	1
4	Active Not Recruiting	Treatment	Driving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care	1
4	Active Not Recruiting	Treatment	Ketamine Induced Agitation	1
4	Active Not Recruiting	Treatment	Major Depressive Disorder (MDD) / Suicidal Ideation	1
4	Completed	Not Available	Disorders of Gallbladder, Biliary Tract and Pancrease	1
4	Completed	Not Available	Failed Moderate Sedation During Procedure	1
4	Completed	Basic Science	Analgesic Drugs / Antinociceptive Agents	1
4	Completed	Basic Science	Pharmacokinetics	1
4	Completed	Basic Science	Rejection, Transplant	1
4	Completed	Diagnostic	Alteration of Cognitive Function / Gastrointestinal Dysfunction	1
4	Completed	Prevention	Adrenocortical Deficiency / Hemodynamics Instability	1
4	Completed	Prevention	Chronic Diseases	1
4	Completed	Prevention	Cognitive Impairments	1
4	Completed	Prevention	Delirium	1
4	Completed	Prevention	Delirium on Emergence / Inhalational Anesthetics Adverse Reaction / Strabismus Following Ocular Surgery	1
4	Completed	Prevention	Elective Orthopedic Surgery	1
4	Completed	Prevention	Emergence Agitation	1
4	Completed	Prevention	Patients Undergoing Puncture of the Bone Marrow	1
4	Completed	Supportive Care	Anesthesia; Reaction	1
4	Completed	Supportive Care	Endoscopy	1
4	Completed	Supportive Care	Hypothermia	1
4	Completed	Supportive Care	IBS / Malignant Neoplasm of Colon / Polyps	1
4	Completed	Supportive Care	Intubation; Difficult	1
4	Completed	Treatment	Abscesses / Pain	1
4	Completed	Treatment	Acute Respiratory Distress Syndrome (ARDS)	1
4	Completed	Treatment	Aggressive Behavior / Depressive State / Feeling Anxious / Postoperative Period / Tiredness	1
4	Completed	Treatment	Anaesthesia / Premedication	1
4	Completed	Treatment	Brain Diseases	1
4	Completed	Treatment	Bronchoscopy	1
4	Completed	Treatment	Cataracts / Phacoemulsification	1
4	Completed	Treatment	Child Behavior / Conscious Sedation Failure During Procedure / Dental Decay	1
4	Completed	Treatment	Cholangiocarcinomas / Choledocholithiasis / Malignant Neoplasm of Pancreas / Pancreatitis	1
4	Completed	Treatment	Colonoscopy / Sedation, Conscious	1
4	Completed	Treatment	Conscious Sedation Failure During Procedure	1
4	Completed	Treatment	Diagnostic Colonoscopy Screening	1
4	Completed	Treatment	Drug Safety / Procedural Sedation	1
4	Completed	Treatment	Early Childhood Caries	1
4	Completed	Treatment	Efficacy and Safety of Mivacurium Chloride for Pediatric Patients	1
4	Completed	Treatment	Endoscopy	1
4	Completed	Treatment	Endoscopy, Gastrointestinal / Moderate Sedation / Propofol / Target Controlled Infusion (TCI)	1
4	Completed	Treatment	Endoscopy / Inflammatory Bowel Diseases (IBD) / Sedation therapy	1
4	Completed	Treatment	Endoscopy / Sedation therapy	1
4	Completed	Treatment	Failed Moderate Sedation During Procedure	1
4	Completed	Treatment	Failed Moderate Sedation During Procedure / Minimally Conscious State	1
4	Completed	Treatment	Feeling Anxious	3
4	Completed	Treatment	Feeling Anxious / Hepatitis, Chronic / Liver Cirrhosis	1
4	Completed	Treatment	Feeling Anxious / Laceration	1
4	Completed	Treatment	Feeling Anxious / Nausea / Pain	1
4	Completed	Treatment	Caudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity	1
4	Completed	Treatment	Gastrointestinal Stroma Tumors / Non Small-cell Lung Cancer / Renal-cell Cancer	1
4	Completed	Treatment	Healthy Volunteers / Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Treatment	Hernia	1
4	Completed	Treatment	Inadequate or Impaired Respiratory Function / Pain	1
4	Completed	Treatment	Intraoperative Analgesic Use / Postcraniotomy Headache / Postoperative Analgesic Use / Postoperative Complications	1
4	Completed	Treatment	Lung Cancers	1
4	Completed	Treatment	Computerized tomography / MRI of liver / Ultrasound	1
4	Completed	Treatment	Major Depressive Disorder (MDD)	1
4	Completed	Treatment	Mechanically Ventilated and Intubated Subjects	1
4	Completed	Treatment	Other Surgical Procedures	1
4	Completed	Treatment	Oxidative Stress / Sedation therapy	1
4	Completed	Treatment	Procedural Sedation	1
4	Completed	Treatment	Sedation therapy	2
4	Completed	Treatment	Sedation, Conscious	1
4	Completed	Treatment	Sepsis / Shock, Septic / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Completed	Treatment	Sleep Quality of Patients Undergoing TURP	1
4	Completed	Treatment	Suicidal Ideation	1
4	Completed	Treatment	Synovitis of osteoarthritis	1
4	Enrolling by Invitation	Treatment	Analgesia, Patient-Controlled / Arthroplasty / Gastric Resection	1
4	Enrolling by Invitation	Treatment	Anesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting	1
4	Enrolling by Invitation	Treatment	Complications / Delirium / Ventilations, Mechanical	1
4	Not Yet Recruiting	Not Available	Children / Dormicum / Sedation, Conscious	1
4	Not Yet Recruiting	Other	Lumbar Punctures / Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement / Sedation, Conscious / Simple Lacerations Less Than 4 cm	1
4	Not Yet Recruiting	Prevention	C.Surgical Procedure; Cardiac / Delirium	1
4	Not Yet Recruiting	Prevention	Critical Illness	1
4	Not Yet Recruiting	Supportive Care	Infertilities	1
4	Not Yet Recruiting	Treatment	Acute Pulmonary Edema	1
4	Not Yet Recruiting	Treatment	Critical Illness / Deep Sedation / Ventilators, Mechanical	1
4	Not Yet Recruiting	Treatment	Crohn's Disease (CD) / Ulcerative Colitis (UC)	1
4	Not Yet Recruiting	Treatment	Preanesthetic Medication	1
4	Not Yet Recruiting	Treatment	Safety and Efficacy of Intranasal Dexmedetomidine	1
4	Recruiting	Basic Science	Severe Sepsis	1
4	Recruiting	Basic Science	Type 2 Diabetes Mellitus	1
4	Recruiting	Diagnostic	Liver Diseases	1
4	Recruiting	Treatment	Acute Agitation, Behavioural Emergency	1
4	Recruiting	Treatment	Anxiety Disorder / Major Depressive Disorder (MDD)	1
4	Recruiting	Treatment	Bladder Tumors / Postoperative Cognitive Dysfunction	1
4	Recruiting	Treatment	Coronary Artery Disease	1
4	Recruiting	Treatment	Dexmedetomidine / Mechanically Ventilated Sedated Patients / Midazolam / Sedation therapy / Ventilations, Mechanical	1
4	Recruiting	Treatment	Feeling Anxious / Pediatric ALL / Procedural anxiety	1
4	Recruiting	Treatment	Flexible Bronchoscopy / Safety / Satisfaction / Sedation therapy	1
4	Recruiting	Treatment	Knee Injuries	1
4	Recruiting	Treatment	Malignant Neoplasm of Prostate	1
4	Recruiting	Treatment	Sedation in Intensive Care Unit Patients	1
4	Recruiting	Treatment	Sedation therapy	1
4	Recruiting	Treatment	Seizures	1
4	Recruiting	Treatment	Terminal Cancer	1
4	Suspended	Treatment	Patients Requiring Diagnostic Gastroscopy Suitable for Sedation / Patients Requiring Diagnostic Gastroscopy With Sedation	1
4	Terminated	Treatment	Anaesthesia therapy	1
4	Terminated	Treatment	Feeling Anxious	1
4	Terminated	Treatment	Orthopedic Procedures / Procedural Sedation / Regional Anesthesia Block	1
4	Unknown Status	Not Available	Obesity, Morbid	1
4	Unknown Status	Basic Science	Hyperalgesia	4
4	Unknown Status	Prevention	Anaesthetic Preconditioning / Myocardial Injury	1
4	Unknown Status	Prevention	Delirium	1
4	Unknown Status	Prevention	Sedative Withdrawal Delirium	1
4	Unknown Status	Treatment	Anaesthesia therapy / Hemodynamics / Oxidative Stress	1
4	Unknown Status	Treatment	Congenital Choledochal Cyst / Congenital Hydronephrosis / Fracture Bone	1
4	Unknown Status	Treatment	Conscious Sedation Failure During Procedure	1
4	Unknown Status	Treatment	Critical Illness / Ventilations, Mechanical	1
4	Unknown Status	Treatment	Delirium	1
4	Unknown Status	Treatment	Dexmedetomidine / Mechanically Ventilated Patients / Midazolam / Sedation therapy	1
4	Unknown Status	Treatment	Emergency	1
4	Unknown Status	Treatment	Failed Conscious Sedation During Procedure	1
4	Unknown Status	Treatment	Hepatic Encephalopathy	1
4	Unknown Status	Treatment	Inflammatory Disorder of Immune System / Sepsis	1
4	Unknown Status	Treatment	Laceration	1
4	Unknown Status	Treatment	Laryngoscopy / Preanesthetic Medication	1
4	Unknown Status	Treatment	Liver Cirrhosis	1
4	Unknown Status	Treatment	Mechanical Ventilation Complication	1
4	Unknown Status	Treatment	Safety of Dexmedetomidine Sedation	1
4	Unknown Status	Treatment	Traumatic Brain Injury (TBI)	2
4	Unknown Status	Treatment	Adjunct to general anesthesia therapy	1
4	Withdrawn	Supportive Care	Alcoholism / Respiration, Artificial	1
4	Withdrawn	Treatment	Postoperative pain	1
4	Withdrawn	Treatment	Sleep	1
Not Available	Active Not Recruiting	Not Available	Aortic Valve Stenosis	1
Not Available	Active Not Recruiting	Not Available	Postoperative Cognitive Dysfunction	1
Not Available	Completed	Not Available	Anaesthesia therapy	1
Not Available	Completed	Not Available	Clinical Indications for Transesophageal Echocardiography	1
Not Available	Completed	Not Available	Early Gastric Cancer / Gastric Adenoma	1
Not Available	Completed	Not Available	Feeling Anxious / Satisfaction / Sedation therapy / Tolerance	1
Not Available	Completed	Not Available	Pain	1
Not Available	Completed	Not Available	Rhytidoplasty	1
Not Available	Completed	Basic Science	Critical Care / Deep Sedation / Sedation, Conscious	1
Not Available	Completed	Basic Science	Healthy Volunteers	1
Not Available	Completed	Basic Science	Pharmacokinetics	1
Not Available	Completed	Basic Science	Saccadic Eye Movements	1
Not Available	Completed	Diagnostic	Conscious Sedation Failure During Procedure	1
Not Available	Completed	Diagnostic	EGD Procedure	1
Not Available	Completed	Diagnostic	Pain	1
Not Available	Completed	Diagnostic	Sacroiliac Joint Pain / Sympathetically Maintained Pain	1
Not Available	Completed	Other	Endobronchial Ultrasound Guided Transbronchial Needle Aspiration	1
Not Available	Completed	Prevention	Akathisia	1
Not Available	Completed	Prevention	Anesthesia Morbidity / Children / Delirium on Emergence	1
Not Available	Completed	Prevention	General Surgery	1
Not Available	Completed	Prevention	General Surgery / Malignant Neoplasm of Prostate	1
Not Available	Completed	Prevention	Pediatric Emergence Agitation and Pain	1
Not Available	Completed	Prevention	Prophylaxis against postoperative nausea and vomiting	1
Not Available	Completed	Prevention	Psychomotor Agitation	1
Not Available	Completed	Supportive Care	Anaesthesia therapy / Body Temperature Changes	1
Not Available	Completed	Supportive Care	Children	1
Not Available	Completed	Supportive Care	Feeling Anxious	1
Not Available	Completed	Supportive Care	Feeling Anxious / Pain	1
Not Available	Completed	Supportive Care	Liver Cirrhosis	1
Not Available	Completed	Supportive Care	Pre Operative Anxiety	1
Not Available	Completed	Supportive Care	Transient Hypertension	1
Not Available	Completed	Treatment	Anaesthesia therapy	1
Not Available	Completed	Treatment	Basal Cell Carcinoma (BCC) / Feeling Anxious / Skin Cancers / Squamous Cell Carcinoma (SCC)	1
Not Available	Completed	Treatment	Chronic Lung Diseases	1
Not Available	Completed	Treatment	Critical Illness	1
Not Available	Completed	Treatment	Echocardiography, Transesophageal	1
Not Available	Completed	Treatment	Endoscopy / Sedation therapy	1
Not Available	Completed	Treatment	Feeling Anxious	1
Not Available	Completed	Treatment	Fractures, Compression	1
Not Available	Completed	Treatment	Hemodynamics After Spinal Anesthesia	1
Not Available	Completed	Treatment	Intubations	1
Not Available	Completed	Treatment	Other Surgical Procedures	1
Not Available	Completed	Treatment	Postoperative Cognitive Functions	1
Not Available	Completed	Treatment	Psychomotor Agitation	1
Not Available	Completed	Treatment	Respiration Disorders	1
Not Available	Completed	Treatment	Sepsis / Shock	1
Not Available	Completed	Treatment	Sepsis / Traumas	1
Not Available	Not Yet Recruiting	Device Feasibility	Sedation therapy / Spinal Anaesthesia	1
Not Available	Not Yet Recruiting	Prevention	Peripheral Obliterative Arteriopathy	1
Not Available	Not Yet Recruiting	Treatment	Brachial Plexus Block / Shoulder Dislocation	1
Not Available	Not Yet Recruiting	Treatment	Obesity, Morbid	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Recruiting	Not Available	Anaesthesia therapy	1
Not Available	Recruiting	Not Available	Cerebral Ischemia-Hypoxia	1
Not Available	Recruiting	Not Available	Depressive State	1
Not Available	Recruiting	Not Available	Gliomas	1
Not Available	Recruiting	Not Available	Psychomotor Agitation	1
Not Available	Recruiting	Basic Science	Amnesia / Anaesthesia therapy / Anesthetics / Pain / Sedation, Conscious	1
Not Available	Recruiting	Diagnostic	Ventricular Tachycardia (VT)	1
Not Available	Recruiting	Health Services Research	Sedation therapy	1
Not Available	Recruiting	Prevention	Intubation; Difficult or Failed	1
Not Available	Recruiting	Treatment	Acute Respiratory Failure	1
Not Available	Recruiting	Treatment	Anoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders	1
Not Available	Recruiting	Treatment	Colonoscopy	1
Not Available	Recruiting	Treatment	Intubated Requiring Sedation for Greater Than 48 Hours	1
Not Available	Recruiting	Treatment	Major Depressive Disorder (MDD) / Severe Depression / Treatment Resistant Depression (TRD)	1
Not Available	Recruiting	Treatment	Postoperative Pain Control / Wrist Injury	1
Not Available	Recruiting	Treatment	Stress, Psychological	1
Not Available	Suspended	Treatment	Paediatric Flexible Bronchoscopy	1
Not Available	Terminated	Not Available	Vesicoureteral Reflux	1
Not Available	Terminated	Treatment	BMI >30 kg/m2 / Sleep Apnea, Obstructive	1
Not Available	Terminated	Treatment	Bipolar Disorder (BD)	1
Not Available	Terminated	Treatment	Respiratory Failure	1
Not Available	Unknown Status	Not Available	Chronic Alcoholism	1
Not Available	Unknown Status	Not Available	Functional disorders of the biliary tract / Pancreatic Diseases	1
Not Available	Unknown Status	Basic Science	Phobic Disorders	1
Not Available	Unknown Status	Prevention	Cystoscopy	1
Not Available	Unknown Status	Screening	Anesthesia Recovery Period / Delirium, Dementia, Cognitive Disorders / Mental Competency / Neurobehavioural Manifestation	1
Not Available	Unknown Status	Supportive Care	Diverticulosis, Colonic / Malignant Neoplasm of Colon / Rectal Carcinoma	1
Not Available	Unknown Status	Supportive Care	Pacemaker Implantation / Pain	1
Not Available	Unknown Status	Supportive Care	Sleeplessness	1
Not Available	Unknown Status	Treatment	Acute Agitation	1
Not Available	Unknown Status	Treatment	Anaesthesia therapy	1
Not Available	Unknown Status	Treatment	Bronchoscopy； / Central Airway Stenosis / Interventional； / Noninvasive Positive Pressure Ventilation / Sedation therapy	1
Not Available	Unknown Status	Treatment	Liver Diseases	1
Not Available	Withdrawn	Not Available	Traumas	1

Pharmacoeconomics

Manufacturers

Apothecon inc div bristol myers squibb
App pharmaceuticals llc
Astrazeneca pharmaceuticals lp
Baxter healthcare corp anesthesia and critical care
Baxter healthcare corp anesthesia critical care
Bedford laboratories div ben venue laboratories inc
Ben venue laboratories inc
Claris lifesciences ltd
Hospira inc
International medicated systems ltd
International medication systems ltd
Taylor pharmaceuticals
Wockhardt ltd
Hlr technology
Apotex inc richmond hill
Hi tech pharmacal co inc
Paddock laboratories inc
Ranbaxy laboratories ltd
Roxane laboratories inc
Hoffmann la roche inc

Packagers

Dosage forms

Form	Route	Strength
Liquid	Intramuscular; Intravenous	1 mg
Liquid	Intramuscular; Intravenous	5 mg
Solution	Buccal	10 mg
Solution	Buccal	2.5 mg
Solution	Buccal	5 mg
Solution	Buccal	7.5 mg
Injection, solution	Intramuscular; Intravenous	10 mg/2mL
Injection, solution	Intramuscular; Intravenous	2 mg/2mL
Injection, solution	Intravenous	.5 mg/mL
Injection, solution	Intravenous	1 mg/mL
Injection	Intramuscular; Intravenous	1 mg/mL
Injection	Intramuscular; Intravenous	10 mg/2mL
Injection	Intramuscular; Intravenous	2 mg/2mL
Injection	Intramuscular; Intravenous	5 mg/mL
Injection, solution	Intramuscular; Intravenous	1 mg/mL
Injection, solution	Intramuscular; Intravenous	5 mg/mL
Syrup	Oral	10 mg/5mL
Syrup	Oral	2 mg/mL
Solution	Intramuscular; Intravenous	1 mg
Solution	Intramuscular; Intravenous	5 mg

Prices

Unit description	Cost	Unit
Midazolam 5 mg/ml	3.9USD	ml
Midazolam-nacl 2 mg/ml inj	2.31USD	ml
Midazolam hcl 5 mg/ml vial	1.18USD	ml
Midazolam-nacl 1 mg/ml inj	1.13USD	ml
Midazolam hcl 2 mg/ml syrup	1.08USD	ml
Midazolam 1 mg/ml isecure syr	0.73USD	ml
Midazolam hcl 1 mg/ml vial	0.26USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	159 °C	PhysProp
water solubility	0.024 mg/mL	Thorsteinn Loftsson and Dagný Hreinsdóttir, 2006

Predicted Properties

Property	Value	Source
Water Solubility	0.00987 mg/mL	ALOGPS
logP	3.89	ALOGPS
logP	3.33	ChemAxon
logS	-4.5	ALOGPS
pKa (Strongest Basic)	6.57	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	30.18 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	99.43 m³·mol^-1	ChemAxon
Polarizability	32.7 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9724
Caco-2 permeable	+	0.8866
P-glycoprotein substrate	Non-substrate	0.5074
P-glycoprotein inhibitor I	Inhibitor	0.5587
P-glycoprotein inhibitor II	Inhibitor	0.8388
Renal organic cation transporter	Inhibitor	0.7476
CYP450 2C9 substrate	Non-substrate	0.7366
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.7194
CYP450 1A2 substrate	Inhibitor	0.8586
CYP450 2C9 inhibitor	Inhibitor	0.7132
CYP450 2D6 inhibitor	Non-inhibitor	0.6887
CYP450 2C19 inhibitor	Inhibitor	0.6554
CYP450 3A4 inhibitor	Non-inhibitor	0.5214
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9001
Ames test	Non AMES toxic	0.8024
Carcinogenicity	Non-carcinogens	0.7703
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	3.1488 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9827
hERG inhibition (predictor II)	Non-inhibitor	0.7379

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0009000000-2411220f611ba30ef225	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0009000000-c724b297ae99edb399d3	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004l-0098000000-b57c162c4eeaad9ef111	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0006-0090000000-a3133528f5491f4c9a6b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-05fs-0290000000-ee126555f849ecfff795	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-0009000000-4ae622c7b53369b0cfb1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-0019000000-00c3c9e2813a454acda1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-002f-0093000000-a8ca99ef6c84536bff07	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0006-0091000000-3edc4aa6f67d99b789a8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0abd-0290000000-aa5e16437618ad2adb86	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-05fs-0490000000-a323090224c5b01e3990	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-004i-0189000000-6e704a4a2a65211394ab	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-03di-0910000000-98021a5812f1663e9397	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-qTof , Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-03di-3839000000-42781254e15bcd5b31b6	View in MoNA

Taxonomy

Description

This compound belongs to the class of chemical entities known as imidazo[1,5-a][1,4]benzodiazepines. These are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Benzodiazepines

Direct Parent

Imidazo[1,5-a][1,4]benzodiazepines

Alternative Parents

Fluorobenzenes / 1,4-diazepines / N-substituted imidazoles / Aryl fluorides / Aryl chlorides / Heteroaromatic compounds / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds

Substituents

Imidazo[1,5-a][1,4]benzodiazepine / Para-diazepine / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid / N-substituted imidazole

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

diazepine (CHEBI:6931 )

Get DrugBank to go!

Structure for DB00683 (Midazolam)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

References

References

References

Transporters

References

References